Physician profile
Kyle Bryans
NPI 1366592958
$604.94
in general payments reported to CMS, 2019-2025
19 companies · $86.71 in 2025
The $86.71 reported for 2025 was less than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $13.30 · 2021: $62.15 · 2022: $108 · 2023: $72.21 · 2024: $37.01 · 2025: $86.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic INC | $114.63 | 2019-2022 | |
| Hitachi Healthcare Americas Corp. | $94.85 | 2019 | |
| Ge Healthcare | $42.37 | 2019-2025 | |
| Celgene Corporation | $34.83 | 2025 | Reblozyl |
| Janssen Biotech, INC. | $34.83 | 2022-2024 | Erleada |
| Siemens Medical Solutions USA, INC. | $32.21 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $30.25 | 2023-2025 | Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $28.29 | 2022 | |
| Blueprint Medicines Corporation | $22.60 | 2023 | Ayvakit |
| Exelixis INC. | $21.06 | 2023 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $20.42 | 2025 | Monoferric |
| Incyte Corporation | $18.83 | 2024 | Pemazyre, Monjuvi |
| Acrotech Biopharma INC. | $18.60 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.03 | 2022 | |
| Cardiva Medical, INC. | $17.62 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.23 | 2022 | |
| Rigel Pharmaceuticals, INC. | $14.96 | 2023 | Tavalisse, Rezlidhia |
| Secura Bio, INC. | $13.30 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Bryans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.